掌腱膜挛缩症患者注射胶原酶后的七年临床疗效：一项前瞻性研究。
Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.
作者信息
De Vitis Rocco, Passiatore Marco, Perna Andrea, Careri Silvia, Cilli Vitale, Taccardo Giuseppe
机构信息
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Università Cattolica del Sacro Cuore, Roma, Italy.
出版信息
J Orthop. 2020 Mar 29;21:218-222. doi: 10.1016/j.jor.2020.03.028. eCollection 2020 Sep-Oct.
Abstract
INTRODUCTION
This investigation is a prospective cohort study examining the use of collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up.
METHODS
Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction.
RESULTS
86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment.
CONCLUSION
CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates.
摘要
引言
本研究是一项前瞻性队列研究，对胶原酶注射（CCH）治疗掌腱膜挛缩症（DD）进行了7年的随访。
方法
45名单指DD患者在单个关节注射CCH。评估包括测量残余被动伸展受限（PED）、功能（使用QuickDASH）和患者满意度。
结果
86.7%的近端指间关节（PIPJ）和65.6%的掌指关节（MPJ）的PED恶化。然而，39名患者（86.7%）仅注射一次就结束了治疗，无需进一步治疗。
结论
CCH提供了一种长期有效的解决方案。复发时有发生，尤其是在PIPJ，发生率可接受。
相似文献
1
Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.
J Orthop. 2020 Mar 29;21:218-222. doi: 10.1016/j.jor.2020.03.028. eCollection 2020 Sep-Oct.
2
CLINICAL RESULTS OF COLLAGENASE TREATMENT FOR DUPUYTREN'S DISEASE: A CASE SERIES STUDY WITH 2-YEARS FOLLOW-UP.
Acta Ortop Bras. 2023 Apr 17;31(spe1):e259218. doi: 10.1590/1413-785220233101e259218. eCollection 2023.
3
Long-term assessment of collagenase treatment for Dupuytren's contracture: A 10-year follow-up study.
World J Orthop. 2024 Apr 18;15(4):355-362. doi: 10.5312/wjo.v15.i4.355.
4
Long-Term Outcomes of Collagenase Clostridium Histolyticum Injection for Palmar Dupuytren's Deformity Correction.
Cureus. 2021 Nov 27;13(11):e19952. doi: 10.7759/cureus.19952. eCollection 2021 Nov.
5
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.
J Hand Surg Am. 2015 Aug;40(8):1597-605. doi: 10.1016/j.jhsa.2015.04.036. Epub 2015 Jun 18.
6
Cost-Effectiveness and Patient Outcomes of Injectable Collagenase to Treat Dupuytren's Contracture.
Cureus. 2021 Dec 20;13(12):e20530. doi: 10.7759/cureus.20530. eCollection 2021 Dec.
7
Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up.
Plast Reconstr Surg. 2020 Jun;145(6):1464-1474. doi: 10.1097/PRS.0000000000006828.
8
Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1-3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients.
Arch Orthop Trauma Surg. 2018 Nov;138(11):1623-1631. doi: 10.1007/s00402-018-3034-6. Epub 2018 Sep 26.
9
Hand function 5 years after treatment with collagenase injection for Dupuytren's disease.
J Hand Surg Eur Vol. 2021 Nov;46(9):985-994. doi: 10.1177/17531934211002383. Epub 2021 Mar 24.
10
Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren's disease in 788 patients: the Austrian register.
Arch Orthop Trauma Surg. 2019 Sep;139(9):1315-1321. doi: 10.1007/s00402-019-03226-3. Epub 2019 Jul 17.
引用本文的文献
1
Therapy for Dupuytren's Disease (II): Collagenase Therapy vs. Limited Fasciectomy-A Long-Term Comparative Study.
Life (Basel). 2025 Jan 10;15(1):76. doi: 10.3390/life15010076.
2
Long-term assessment of collagenase treatment for Dupuytren's contracture: A 10-year follow-up study.
World J Orthop. 2024 Apr 18;15(4):355-362. doi: 10.5312/wjo.v15.i4.355.
3
Comparing Complications and Patient Satisfaction Following Injectable Collagenase Versus Limited Fasciectomy for Dupuytren's Disease: A Systematic Review and Meta-Analysis.
Cureus. 2024 Jan 29;16(1):e53147. doi: 10.7759/cureus.53147. eCollection 2024 Jan.
4
Delayed vascular complication after collagenase injection for Dupuytren disease.
BMC Musculoskelet Disord. 2023 Oct 23;24(1):837. doi: 10.1186/s12891-023-06964-z.
5
Epidemiology and aetiology of male and female sexual dysfunctions related to pelvic ring injuries: a systematic review.
Int Orthop. 2021 Oct;45(10):2687-2697. doi: 10.1007/s00264-021-05153-8. Epub 2021 Aug 10.
6
External Screw-Threaded Traction Device Helps Optimize Finger Joint Mobility in Severe Stage III and IV Dupuytren Disease.
Med Sci Monit. 2021 Apr 22;27:e929814. doi: 10.12659/MSM.929814.
7
COVID-19 and hand surgery: the perspective of an Italian hand therapist.
Hand Surg Rehabil. 2021 Apr;40(2):208. doi: 10.1016/j.hansur.2020.11.006. Epub 2020 Dec 10.
8
Alternative Strategies of Home Therapy in Clinical Orthopaedics during COVID-19 Pandemic: a Hand Surgeon Perspective.
Malays Orthop J. 2020 Jul;14(2):154-155. doi: 10.5704/MOJ.2007.006.
9
Feasibility of Homodigital Flexor Digitorum Superficialis transposition, a new technique for A2-C1 pulleys reconstruction: A kinematic cadaver study.
J Orthop. 2020 Sep 8;21:483-486. doi: 10.1016/j.jor.2020.09.001. eCollection 2020 Sep-Oct.
本文引用的文献
1
Surgical fasciectomy versus collagenase injection in treating recurrent Dupuytren disease: study protocol of a randomised controlled trial.
BMJ Open. 2019 Feb 25;9(2):e024424. doi: 10.1136/bmjopen-2018-024424.
2
Five-year results after collagenase treatment of Dupuytren disease.
J Hand Surg Eur Vol. 2018 Oct;43(8):841-847. doi: 10.1177/1753193418790157. Epub 2018 Aug 2.
3
DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture.
BMJ Open. 2018 Mar 28;8(3):e019054. doi: 10.1136/bmjopen-2017-019054.
4
Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.
Int Orthop. 2018 Apr;42(4):859-866. doi: 10.1007/s00264-017-3690-0. Epub 2017 Nov 23.
5
Difference in Success Treating Proximal Interphalangeal and Metacarpophalangeal Joints with Collagenase: Results of 208 Treatments.
Plast Reconstr Surg Glob Open. 2017 Apr 25;5(4):e1275. doi: 10.1097/GOX.0000000000001275. eCollection 2017 Apr.
6
Trends in the Treatment of Dupuytren Disease in the United States Between 2007 and 2014.
Hand (N Y). 2017 Jan;12(1):13-20. doi: 10.1177/1558944716647101. Epub 2016 May 3.
7
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.
Br Med Bull. 2016 Jun;118(1):149-58. doi: 10.1093/bmb/ldw020. Epub 2016 May 5.
8
Patient Satisfaction With Collagenase.
J Hand Surg Am. 2016 Jun;41(6):689-97. doi: 10.1016/j.jhsa.2016.03.003. Epub 2016 Apr 28.
9
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.
J Hand Surg Am. 2015 Aug;40(8):1597-605. doi: 10.1016/j.jhsa.2015.04.036. Epub 2015 Jun 18.
10
Degenerative facet joint changes in lumbar percutaneous pedicle screw fixation without fusion.
Orthop Traumatol Surg Res. 2015 May;101(3):375-9. doi: 10.1016/j.otsr.2015.01.013. Epub 2015 Mar 25.
Zotero 插件